Table 3 Comparison between RB1 / CDH1 methylation and HPV/EBV infection, reporting the percentages of methylated cases among HPV/EBV positive cases
Control/Lesion Type | Methylation Status | |||||||
|---|---|---|---|---|---|---|---|---|
RB1 | CDH1 | |||||||
HPV+, n (%)* | EBV+, n (%) | HPV and EBV+, n (%) | HPV and EBV-, n (%) | HPV+, n (%) | EBV+, n (%)** | HPV and EBV+, n (%) | HPV and EBV-, n (%) | |
Control (n = 15) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (20.0) | 1 (25.0) | 0 (0.0) | 0 (0.0) | 1 (20.0) |
LSIL (n = 17) | 1 (9.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (15.3) | 0 (0.0) | 0 (0.0) |
HSIL (n = 15) | 4 (50.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (50.0) | 2 (28.6) | 2 (50.0) | 0 (0.0) |
Cancer (n = 18) | 7 (50.0) | 7 (63.6) | 6 (60.0) | 1 (33.3) | 4 (28.6) | 5 (45.5) | 4 (40.0) | 1 (33.3) |
Total (n = 65) | 12 (32.4) | 7 (17.9) | 6 (25.0) | 2 (15.3) | 9 (24.3) | 9 (23.1) | 6 (25.0) | 2 (15.3) |